Bicara Therapeutics Inc. (NASDAQ: BCAX)

Introduction

Bicara Therapeutics Inc. is a clinical-stage biotechnology company developing bifunctional biologics that combine tumor-targeting antibodies with immunomodulatory payloads. Its lead program, ficerafusp alfa (formerly BCA101), is a dual-action EGFR/TGF-β inhibitor currently under clinical development for multiple solid tumor types.

Key Stock Data (as of May 23, 2025)

Metric	Value
Share Price	$8.87
Year-to-date Price Change	–43.36%
Daily Volume	2,002,497
52-Week Range	$7.80 – $28.09
Intraday Market Cap	$484.8 million
Exchange	NASDAQ (BCAX)

---

Corporate Structure

• Founded: 2020
• Headquarters: Boston, Massachusetts
• Employees: 51–200 (per LinkedIn)
• Industry: Biotechnology Research
• Specialties: Immunotherapy, Targeted Oncology, Drug Discovery

---

Recent Developments

• December 12, 2023
  Completed an oversubscribed $165 million Series C financing co-led by Braidwell LP and TPG. Proceeds will be directed to the clinical development of ficerafusp alfa in head and neck, non–small cell lung, and cutaneous squamous cell carcinomas.

• February 11, 2025
  Announced enrollment of the first patients in FORTIFI-HN01, a pivotal Phase 2/3 trial of ficerafusp alfa in combination with pembrolizumab in first-line recurrent/metastatic head and neck squamous cell carcinoma (HNSCC).

• May 13, 2025
  Filed Form 10-Q for the quarter ended March 31, 2025, and current report on Form 8-K (Items 2.02, 9.01) detailing clinical and governance updates.

• May 15, 2025
  Schedule 13G filing discloses that Vestal Point Capital, LP and Ryan Wilder hold 2,768,975 shares, representing 5.1% of outstanding stock, with shared voting and dispositive power.

• May 23, 2025
  Published an interim Phase 1/1b data abstract for ficerafusp alfa in first-line recurrent/metastatic HNSCC; a conference call is scheduled for June 1, 2025, during ASCO 2025.

---

Financial and Strategic Analysis

Balance Sheet Highlights

• Cash and Cash Equivalents: $462.1 million (most recent quarter)
• Total Debt/Equity: 0.13%
• Trailing 12-Month Net Income to Common: –$92.3 million
• Diluted EPS (TTM): –$1.69
• Return on Equity (TTM): –27.26%

Trading and Valuation Metrics

• Average Daily Volume: 588,122 shares
• Price/Book (most recent quarter): 1.86
• Profit Margin: 0.0%

Strategic Considerations

• Capital Runway: Cash reserves plus $165 million from the Series C financing support ongoing registrational trials.
• Ownership Concentration: A 5.1% stake held by a single investor group may influence governance.
• Pipeline Advancement: Transitioning to late-stage development with FORTIFI-HN01; additional data readouts are anticipated in 2025–2026.

---

Market Position and Industry Context

• Head and Neck Squamous Cell Carcinoma (HNSCC):
  – Sixth most common cancer worldwide (approximately 890,000 cases and 450,000 deaths reported in 2018).
  – Incidence is projected to increase by 30% by 2030.
  – Approximately 80% of recurrent/metastatic cases are HPV-negative and face unmet therapeutic needs.

• Competitive Landscape:
  – Existing EGFR inhibitors (e.g., cetuximab) and immune checkpoint inhibitors (e.g., pembrolizumab, nivolumab) are in use.
  – Bicara's bifunctional antibody aims to simultaneously inhibit tumor growth and modulate the tumor microenvironment.

• Industry Trend:
  – There is a growing emphasis on multispecific and bifunctional biologics to potentially enhance therapeutic efficacy and improve patient outcomes in solid tumors.

---

tl;dr

• Through May 23, 2025, BCAX shares trade at $8.87 (–43.36%).
• December 12, 2023: Completed $165 million Series C financing.
• February 11, 2025: First patients enrolled in pivotal Phase 2/3 FORTIFI-HN01 trial.
• May 23, 2025: Phase 1/1b trial data abstract published; ASCO call set for June 1, 2025.
• Outlook: Data readouts from registrational trials and substantial cash reserves may support potential filings for accelerated and full approvals.